
|Videos|July 5, 2017
Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases
Author(s)Rachel A. Freedman, MD, MPH
Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
4
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
5































